Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series
暂无分享,去创建一个
A. Slišković | H. Holik | J. Samardžić | L. Ganoci | L. Šimičević | T. Božina | M. V. Kirhmajer | Jozefina Palić
[1] N. Limdi,et al. Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients , 2022, Frontiers in Pharmacology.
[2] A. Corsini,et al. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice , 2022, Pharmaceutics.
[3] M. Niemi,et al. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users , 2021, Clinical pharmacology and therapeutics.
[4] I. Cascorbi,et al. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? , 2021, Expert opinion on drug metabolism & toxicology.
[5] M. Ajmal,et al. Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review , 2021, Cardiovascular therapeutics.
[6] Huijun Sun,et al. Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant , 2021, Cardiovascular Drugs and Therapy.
[7] F. Lamoureux,et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review , 2021, Journal of personalized medicine.
[8] Takahiko Kinjo,et al. Impact of gene polymorphisms in drug‐metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation , 2020, Basic & clinical pharmacology & toxicology.
[9] E. Stecker,et al. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges , 2020, Journal of the American Heart Association.
[10] William R Arnold,et al. CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design. , 2020, Pharmacology & therapeutics.
[11] D. Garcia,et al. Should we monitor the direct oral anticoagulants? , 2020, Journal of Thrombosis and Thrombolysis.
[12] Nadine Shehab,et al. Emergency Visits for Oral Anticoagulant Bleeding , 2019, Journal of General Internal Medicine.
[13] P. Bochkov,et al. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery , 2019, High Blood Pressure & Cardiovascular Prevention.
[14] Rivaroxaban , 2019, Reactions Weekly.
[15] J. Zolnerciks,et al. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors , 2019, Expert opinion on drug metabolism & toxicology.
[16] Q. Xiang,et al. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis. , 2018, Current pharmaceutical design.
[17] V. Stepanov,et al. A comprehensive study revealed SNP–SNP interactions and a sex-dependent relationship between polymorphisms of the CYP2J2 gene and hypertension risk , 2018, Hypertension Research.
[18] J. Dogné,et al. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study , 2018, Thrombosis Journal.
[19] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[20] Yitian Zhou,et al. Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects , 2017, Clinical pharmacology and therapeutics.
[21] M. Loriot,et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin , 2017, Journal of thrombosis and haemostasis : JTH.
[22] Y. Daali,et al. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect , 2016, Front. Pharmacol..
[23] S. Zhai,et al. Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis , 2015, PloS one.
[24] I. Cascorbi,et al. Functional Gene Variants of CYP3A4 , 2014, Clinical pharmacology and therapeutics.
[25] W. Mueck,et al. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban , 2013, Clinical Pharmacokinetics.
[26] V. Haufroid,et al. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. , 2013, Pharmacogenomics.
[27] Chapter 1: Definition and classification of CKD , 2012, Kidney International Supplements.
[28] V. Haufroid,et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.
[29] W. Sadee,et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.
[30] Russ B Altman,et al. PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. , 2011, Pharmacogenetics and genomics.
[31] Francesco Pignatti,et al. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. , 2010, The oncologist.
[32] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[33] T. Ishikawa,et al. Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations , 2009, Pharmaceutical Research.
[34] M. Pirmohamed,et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research , 2007, The Pharmacogenomics Journal.
[35] M. Shimizu,et al. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[36] Y. Sugiyama,et al. Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.
[37] M. Fromm,et al. Importance of P-glycoprotein at blood-tissue barriers. , 2004, Trends in pharmacological sciences.
[38] V. Smirnov,et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. , 2018, Genetic testing and molecular biomarkers.
[39] J. Stockman,et al. A New Equation to Estimate Glomerular Filtration Rate , 2011 .